|Society of Surgical Oncology (SSO)|
March 21-24, 2012
Orlando World Center Marriott Hotel
|INTIO representatives attended and exhibited ClearStart•SVM™ at the annual meeting of SSO, an organization representing cancer surgery specialists from around the world.|
|Society of Interventional Radiology (SIR)|
March 24-29, 2012
San Francisco, CA
|We exhibited ClearStart•SVM™ at the annual meeting of SIR, where key interventional radiologists saw what SVM can do for them.|
|European Congress on Interventional Oncology (ECIO)|
April 25-28, 2012
Firenze Expo - Palazzo dei Congressi
In April, INTIO exhibited at the 3rd ECIO a leading international congress on interventional oncology.
|Global Embolization Symposium and Technologies (GEST)|
May 3-6, 2012
New York, NY
Sheraton New York
SVM also has a role to play in planning and assessing embolic therapies, from TAE, to TACE, to Drug Eluting
beads and Y-90 radioembolization.
|American Society of Clinical Oncology (ASCO)|
June 1-5, 2012
SVM has the potential to play a major role in the assessment of imaging response of tumors to drug therapy in clinical trials.
|World Conference on Interventional Oncology (WCIO)|
June 14-17, 2012
Drs. David Gustafson and Luduan Zhang of INTIO were co-authors of an abstract that was presented at WCIO on June 15 during the 8:00 session (8:16-8:24 a.m.).
The abstract entitled, “Tumor response assessment in hepatocellular carcinoma: Efficacy of segmentation and automated volumetric measurements using triple-phase contrast-enhanced computed tomography scans before and after loco-regional therapy.” Other contributing authors include Khairuddin Memon, M.D. and Professor Riad Salem, M.D. @ Northwestern University, Chicago, IL and Dania Cioni, M.D and Professor Riccardo Lencioni, MD, PhD @ Pisa University, Pisa, Italy.
The abstract was presented by Dr. Luduan Zhang, Sr. Staff Scientist at INTIO. Click here for a copy of the abstract.
|International Liver Cancer Association (ILCA)|
September 14-16, 2012
InterContinental Hotel Berlin
|SVM has shown itself to be capable of accurately assessing primary liver tumors, the home turf for ILCA.|
|Cardiological and Interventional Radiological Society of Europe (CIRSE)|
September 15-19, 2012
Centro de Congressos de Lisboa
|The companion society to SIR in the USA, CIRSE is a major interventional radiology forum with leaders in this field from around the world in attendance.|